Life Sciences Litigation Insights: April 2022
CRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this issue, we share notable cases from 2021 and...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
New product introductions in the life sciences sector are frequently complex, costly, and time-consuming undertakings, and collaborations between companies are common. Disputes may arise at all stages of development and commercialization. Our expertise helps clients navigate litigated and arbitrated disputes involving drug development and commercialization and analyze relevant commercial factors (size of the opportunity, therapeutic area, business risks, etc.). CRA has provided expert reports and testimony evaluating development and commercialization efforts and assessing damages associated with alleged contractual breaches and other commercial issues.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comCRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this issue, we share notable cases from 2021 and...
What is the value of an “all natural” label to consumers and the company? Does the presence of the label affect consumer purchase decisions? If so, how should...